<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512029</url>
  </required_header>
  <id_info>
    <org_study_id>18F-AV-1451-A12</org_study_id>
    <nct_id>NCT02512029</nct_id>
  </id_info>
  <brief_title>18F-AV-1451 PET Imaging in TBI</brief_title>
  <official_title>18F-AV-1451 PET Imaging in Subjects With Subacute Traumatic Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Avid Radiopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Avid Radiopharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate imaging characteristics of 18F-AV-1451 in subjects with subacute
      traumatic brain injury.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TBI Biomarker Analysis</measure>
    <time_frame>75-105 minutes postinjection</time_frame>
    <description>18F-AV-1451 uptake will be compared in subjects with TBI and controls.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship Between Clinical Presentation and Tau Deposition (MMSE)</measure>
    <time_frame>75-105 minutes postinjection</time_frame>
    <description>The relationship between 18F-AV-1451 uptake and clinical measures using Mini-Mental State Examination (MMSE).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in tau deposition over time</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the rate of change of tau deposition as measured by 18F-AV-1451 uptake over time.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relationship Between Clinical Presentation and Tau Deposition (BIS-11)</measure>
    <time_frame>75-105 minutes postinjection</time_frame>
    <description>The relationship between 18F-AV-1451 uptake and clinical measures using Barratt Impulsivity Scale 11 (BIS-11)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>TBI Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with history of recent subacute Traumatic Brain Injury (TBI) will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451 2 to 6 weeks following injury. They will return for a follow-up injection approximately 6 months following injury.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitively healthy volunteer subjects will receive a single IV injection, 370 megabecquerel (MBq) [10 millicurie (mCi)] of 18F-AV-1451.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18F-AV-1451</intervention_name>
    <arm_group_label>TBI Subjects</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <other_name>[F-18]T807</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        TBI Subjects

        Inclusion Criteria:

        TBI Subjects

          -  Subjects that have consented and are currently enrolled in either Transforming
             Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI), Evaluation,
             Pathogenesis, and Outcome of Subjects with or Suspected Traumatic Brain Injury
             Protocol Number: CNS: 10-N-N122, or Evaluation and Diagnosis of Potential Research
             Subjects with Traumatic Brain Injury (TBI): Protocol Number: 11-N-0084

          -  History of having sustained a TBI &lt; 6 weeks prior to enrollment

          -  Can tolerate PET and MRI scan procedures

        Control Subjects

          -  MMSE â‰¥ 28

          -  No significant history of cognitive impairment

          -  No prior history of TBI

          -  Can tolerate PET and MRI scan procedures

        Exclusion Criteria:

          -  Have behavior dysfunction that is likely to interfere with imaging

          -  Are claustrophobic or otherwise unable to tolerate the imaging procedure

          -  Have current clinically significant cardiovascular disease, or clinically significant
             abnormalities on screening ECG

          -  A history of additional risk factors for Torsades de Pointes (TdP) or are taking drugs
             that are known to cause QT-prolongation

          -  Have a current clinically significant infectious disease, endocrine or metabolic
             disease, pulmonary, renal or hepatic impairment, or cancer

          -  Are females of childbearing potential who are not surgically sterile, not refraining
             from sexual activity or not using reliable methods of contraception

          -  Have had a non-study related radiopharmaceutical imaging or treatment procedure within
             7 days prior to the 18F-AV-1451 imaging session

          -  Have current alcohol dependence or alcohol dependence within the past 1 year

          -  Are currently participating in another interventional clinical trial

          -  Have evidence of a penetrating brain injury

          -  Have participated in contact sports in college or after high school age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Chair</role>
    <affiliation>Avid Radiopharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NIH Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>February 4, 2016</last_update_submitted>
  <last_update_submitted_qc>February 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

